• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
Home
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
  • Podcasts
  • Resources
    • Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
Search Icon
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
  • Podcasts
  • Resources
    • Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events

Kyowa Hakko Kirin

Biotech

Mei, with Bayer and Gilead in its sights, posts pivotal data

The pivotal trial linked zandelisib to a 70% response rate but leaves scope to question whether the drug can crack a competitive space.
Nick Paul Taylor Nov 30, 2021 9:10am

Amgen reveals midphase eczema data behind its $400M bet

Oct 4, 2021 7:10am

Kyowa Kirin licenses AM-Pharma phase 3 asset for up to $289M

Sep 8, 2021 9:28am

Amgen reunites with Kyowa Kirin in $400M dermatitis deal

Jun 1, 2021 4:00am

MEI Pharma nabs $100M upfront in new Kyowa Kirin deal

Apr 14, 2020 7:15am

GSK files for Japanese approval of oral anemia drug

Aug 21, 2019 8:54am
Home
  • Connect
    • The Team
    • Advertise
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
  • ©2022 Questex LLC All rights reserved.
  • Terms of use
  • Privacy Policy